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Cold ischemia time is a risk factor for the development of
acute renal failure in the immediate post-transplant period. In
this study, we aimed to determine if intravenous fructose-1,
6-diphosphate (FDP), given before nephrectomy, attenuates
renal cell injury in a cold ischemia model. Male adult Wistar
rats were subjected to infusion of either FDP 350 mg/kg
(group F, n¼ 6), an equal volume of 0.9% NaCl (group S,
n¼ 6), an equal volume/osmolality of mannitol (group M,
n¼ 6) or no infusion (group C, n¼ 7). Kidneys were then
perfused in situ with Collins solution and nephrectomy was
performed. Other kidney slices were stored in Collins solution
at 41C. Adenosine triphosphate (ATP) levels and lactate
dehydrogenase (LDH) release were examined at 0, 24, 48
and 72 h. Other slices, obtained after 50 min immersion in
Collins solution at 371C, were frozen for characterization of
cytoskeletal preservation using phalloidin-FITC staining.
Apical fluorescence intensity of proximal tubule cells,
indicative of the F-actin concentration, was measured in a
fluorescence microscope interfaced with computer image
analysis system. Adenosine triphosphate levels, after up to
72 h of tissue incubation, were higher (Po0.05) in the FDP
group when compared to other groups. In addition, LDH
release was smaller (Po0.0001) in the FDP group. The F-actin
concentration of proximal tubule cells cells was greater in the
FDP group (Po0.0001). Results indicate that FDP is a useful
tool to increase tissue viability in a rat kidney subjected to
cold ischemia, by maintaining ATP cell content, decreasing
LDH release and preventing microfilament disruption of
proximal tubule cells.
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In cadaveric renal transplantation, cold ischemia time is a
risk factor for the development of acute renal failure.1 United
States Renal Data Service data show that the frequency of
delayed graft function (DGF) increases by 23.4% for every 6 h
of cold ischemia, and is associated with diminished kidney
allograft survival.2
DGF syndrome, like postischemic acute renal failure in the
rat, is precipitated by complete interruption of the renal
blood supply, causing severe cellular adenosine triphosphate
(ATP) depletion. Cellular processes, which include protein
synthesis, lipogenesis and membrane transport, become
impaired when ATP is markedly depleted and ATP depletion
causes early alterations in the actin cytoskeleton, resulting in
loss of the membrane domains and cell detachment.3 The
preservation of ATP levels can be crucial, to maintain cell
integrity and prolong cell survival.
Fructose-1,6-diphosphate (FDP) is an intracellular meta-
bolite, that enhances carbohydrate utilization by stimulating
glycolysis and, simultaneously, inhibiting gluconeogenesis.4
The potential advantage of using FDP as the initial substrate
is that, whereas the net yield of the anaerobic metabolism
of one mole of glucose is two ATP moles, one mole of
FDP metabolized in the same conditions would result in a net
gain of four ATP moles since FDP does not require
phosphorylation.5,6
It has been demonstrated, using 13C-nuclear magnetic
resonance spectroscopy, that exogenous FDP can cross the
plasma membrane.7–9 Labelled FDP was measured in blood,
where it reaches the highest amount 10 min after adminis-
tration. The hydrolytic activity of FDP was measured in
organ extracts and was found to be maximal in the kidney.10
Exogenous FDP, entering the cells, can stimulate the
glycolytic pathway in three different ways (Figure 1): FDP
can be hydrolyzed by fructose-1,6-diphosphatase, and
increase fructose-6-phosphate levels, which can be used as
a substrate for endogenous FDP production; FDP can
activate phosphofructokinase, bypassing the acidosis-
induced metabolic block; and FDP can directly stimulate
the activity of piruvatekinase, increasing the production of
pyruvate.
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For years, FDP has been used both clinically and
experimentally during hypoxia and ischemia to facilitate
metabolic recovery after hypoxic or ischemic insult. Pretreat-
ment with FDP provides histologic and functional protec-
tion, 24 h after the insult, in rats subjected to 30 min of
bilateral renal artery occlusion.11 Post-treatment, with FDP
infusion beginning 10 min after release of the renal artery
clamps, also provided significant, although not complete,
functional and histologic protection from renal damage.12
FDP administration attenuates lung injury,13 prevents
reperfusion injury in rat intestines14 and improves motility
of spermatazoa.15 Moreover, FDP prevents ischemia-induced
brain damage in rabbits,16 attenuates cyclosporin neprotoxi-
city17 and also has a beneficial effect in patients with coronary
artery disease.18,19 FDP reduces postischemic reperfusion
injury in heart,20 liver,21 and heart22 transplantation, and
reduces the mortality rate in experimental sepsis.23,24
The present study intended to determine whether intrave-
nous administration of FDP in rats, prior to nephrectomy,
improves renal tissue preservation during cold ischemia.
RESULTS
According to the data, soon after the infusion of Collins
solution, renal cells progressively lost viability.
Figure 2 shows the cellular ATP content over 72 h.
Throughout the entire procedure there was a significant
decrease in all groups, but ATP content was better preserved
in the FDP (F) group (Po0.05). FDP infusion led to a
maintenance of cellular ATP content in the first 24 h followed
by a gradual decrease not seen in other groups.
Figure 3 shows the lactate dehydrogenase (LDH) leakage
from slices over 72 h. LDH leakage, taken as a measure of
plasma membrane damage, was directly proportional to
ischemia time. At time zero, LDH activity was already present
in the supernatant of all groups, probably as a consequence of
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Figure 1 | The glycolytic pathway. Grey headed arrows indicate possible fates and actions of exogenous FDP in glucose metabolism.
0
0 24 48 72
2
3
Hours
AT
P 
(nm
ol/
mg
/pr
ote
in) C groupS group
M group
F group
∗P<0.05 versus C, S and M
∗
∗
∗
Figure 2 | ATP levels in renal slices over 72 h of tissue incubation.
There was a significant decrease in the C, S and M groups over
72 h. In the F group, there was no decrease in ATP content in the
first 24 h, followed by a progressive decrease but levels were kept
higher in the F group in comparison to the C, S and M groups at
24, 48 and 72 h.
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Figure 3 | LDH release from renal slices into medium over 72 h of
tissue incubation. Data represent mean7s.e.m. There was a
significant increase in LDH release in all groups. From 24 to 72 h the
release was in the order of (Po0.05) C4S4M4F.
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cellular ischemia during the process of renal perfusion,
nephrectomy, tissue preparation and incubation. A progres-
sive and gradual increase in LDH leakage was observed in all
groups at 24, 48 and 72 h of cold ischemia. In the saline (S)
and the mannitol (M) groups, LDH leakage was lower than
in the control (C) group (Po0.0001) and the FDP (F) groups
showed lower LDH leakage (Po0.0001) when compared to
all other groups at 24, 48 and 72 h.
Histological examination
Following 50 min of cold ischemia, brush border microfila-
ments were intensely stained in the FDP (F) group, becoming
disorganized and disrupted in other groups. The greater
apical fluorescence in the FDP (F) group (Po0.0001)
represents better preservation of apical microfilament
integrity than that in the control (C), saline (S) and mannitol
(M) groups. There was no significant statistical difference
among other groups (Figure 4).
DISCUSSION
DGF is the most common allograft complication in the
immediate post-transplant period and is clearly associated
with poor allograft survival. The occurrence of DGF
correlates with cold ischemia time, which is a critical
nonperfusion period, occurring between donor nephrectomy
and transplantation – typically between 10 and 30 h.25,26 The
major renoprotective maneuver is the storage of the kidney
on ice to limit oxygen requirements of renal cells.26
Strategies to decrease the rates of DGF have evolved,
focusing on the donor management, organ procurement and
preservation techniques, recipient fluid management and
pharmacological agents. Nevertheless, rates of DGF in
cadaveric renal transplantation range from 10 to 60%.27
Improvement in early renal function, preventing acute
tubular necrosis, should be a primary goal in cadaveric renal
transplantation in order to optimize early and long-term
results. The preventive administration of FDP could attenuate
renal ischemic injury and act as an alternative energy source
under anaerobic conditions in cadaveric renal transplantation.
We observed, in all groups, a progressive decrease in ATP
cellular content, up to 72 h. However, exogenous FDP
administration, previous to the induction of ischemia, was
found to attenuate the ATP concentration rate reduction, as
also demonstrated by Gobbel et al.28 in hypoxic cerebral
endothelial cells. Rats subjected to equal volume infusion
(S group) or to equal volume-osmolality infusion (M group)
had a greater ATP cellular content than the C group rats. This
suggests that increasing volume and/or plasmatic osmolality
before organ withdrawal can protect the cell, probably by
preventing cell tubular edema.29 However, exogenous FDP
had a still greater effect, superior to saline and mannitol,
suggesting involvement of additional mechanisms, unrelated
to plasma volume status and plasma osmolality. Further-
more, we may speculate that intracellular FDP, acting as a
source of ATP, may prevent cell edema and protect renal cells
from ischemic damage.
The present study showed that LDH leakage, taken as a
measure of plasma membrane damage, is directly propor-
tional to ischemia time as observed in other studies.29,30 We
noticed, during the observational period, that there was a
gradual and progressive LDH leakage in all groups studied. At
time 0 h, LDH activity had already increased in all groups,
probably due to ischemia during renal perfusion, tissue
preparation and incubation. Over time, the saline (S) and
mannitol (M) groups presented lower LDH leakage than the
control (C) group. This suggests that increasing the volume
and/or plasmatic osmolality before organ withdrawal can
protect the cell, probably by preventing cell tubular edema.31
However, FDP administration induced smaller LDH leakage
than saline and mannitol, suggesting, again, that FDP had an
effect beyond plasmatic expansion and osmolality effect.
Possibly, FDP intravenous administration, prior to ischemia,
had a specific effect, acting as an energetic substrate to
anaerobic metabolism in the cell, which, subsequently, would
provide ATP to cell metabolism and protect the cell membrane.
Parallel to the functional changes, distinct structural
alterations occur, predominantly within the proximal tubule,
during ischemic injury. ATP is required for regulation and
maintenance of the cellular cytoskeleton. Numerous surface
membrane alterations occur in a time-dependent fashion
during ischemic injury. These include changes in microvilli
morphology, tight junction integrity, cell attachment and
surface membrane polarity.32
Molitoris32 observed that ATP depletion in renal epithelial
cells causes loss of cell polarity, a process that is reversible
when cells recover from ATP depletion. These investigators
showed that the Naþ -Kþ -ATPase, normally restricted to the
basolateral surface, is rapidly redistributed to the apical
membrane during ischemia, reducing proximal reabsorption
of Naþ and other filtered ions, thereby enhancing their
delivery to the macula densa and activating glomerular
filtration rate-mediated afferent vasoconstriction.33
Phalloidin binds to the pre-existing F-actin filaments of
the cell and is therefore an excellent tool to determine cellular
degree of injury.34 In the present study, F-actin concentration
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Figure 4 | F-actin concentration in the proximal tubule following
50 min of cold ischemia. Apical F-actin concentration was
significantly higher in the F group than in the C, S and M groups.
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alterations were quantitatively analyzed by proximal tubule
cells fluorescence intensity after 50 min of cold ischemia.
Apical F-actin concentration was lower in the control (C)
group and higher in the FDP (F) group. However, the
intravenous infusion of the saline or mannitol solution was
not able to decrease microfilament disruption during ischemia
when compared to the control group. The apical microfila-
ments in vivo depend on intracellular ATP levels. Therefore,
infusion of a substance that could accelerate the glycolytic
pathway and enhance ATP production could prevent apical
microfilament disruption, as shown in the FDP group.
In conclusion, in vitro, FDP was an efficient tool in the
prevention of cell damage secondary to ischemia, in vitro.
Other studies are necessary to establish in vivo safety and
advantages of using FDP in humans.
MATERIALS AND METHODS
Experimental protocol
All procedures followed the institutional guidelines for the care and
use of experimental animals. Twenty-five male Wistar rats weighing
272727 g were housed in a light controlled room with a 12 h light/
dark cycle, and were allowed access to food and water ad libitum.
They were divided into four groups: the FDP group (group F, n¼ 6)
received intravenous (i.v.) FDP in distilled water, 350 mg/kg (57 mg/
ml) at a rate of 30 mg/min; the mannitol group (group M, n¼ 6)
received i.v. mannitol dissolved in distilled water (52 mg/ml) – the
solution having equal osmolality to that of the F group (298 mOsm/
kg/H2O); the saline group (group S, n¼ 6) received i.v. sodium
chloride 0.9% – given in a volume equal to that of the FDP; the
control group (group C, n¼ 7) consisted of sham-operated animals.
The rate of infusion (0.4 ml/min) was controlled by a syringe
pump. Rats were anesthetized with ether and a polyethylene catheter
(PE-50) was inserted into the left femoral vein for fluid and drug
administration. At 10 min after the fluid and drug administration, a
thoraco-abdominal incision was performed and a polyethylene catheter
(PE-160) was introduced into the left ventricle to allow perfusate
solution input; the vena cava was cut to allow perfusate solution
output. Animals were perfused for 40 min with a sterile saline solution
containing heparin (10 U/ml), followed by infusion with Collins
solution (with the addition of verapamil 0.01 mg/ml). The kidneys
were then exposed, and the animals were submitted to bilateral
nephrectomy. The organs were decapsulated and 0.3 mm slices were
obtained. One slice was prepared for histological examination and
another was immediately prepared for biochemical analysis (time 0 h).
All the others were placed on Petri dishes containing Collins solution,
stored at 41C, processed and analyzed at 24, 48 and 72 h.
Biochemical analysis
Before ATP and LDH measurements, each kidney tissue sample was
incubated for 2 h at 371C in a medium composed of 125 mM NaCl,
6 mM KCl, 1 mM CaCl2, 1.2 mM MgSO4, 1 mM NaHPO4, 10 mM
glucose and 15 mM N-2-hydroxyethylelpiperizine-N0-2-ehanesulfonic
acid, pH 7.4. After incubation, the sample was sonicated,
homogenated and centrifuged. Then, medium and homogenate
assays were prepared and subjected to analysis.
ATP processing and analysis at 0, 24, 48 and 72 h
Tissue ATP extraction was performed according to the method
described by Zhang and Lindup.35 Kidney slices were placed in 70%
ethanol and ethylenediaminetetraacetic acid 2 mM, and homo-
genized. After homogenization, 20% trichloroacetic acid (1 ml) was
added to the sample to precipitate the tissue proteins and then
centrifuged. Finally, 500 ml was taken from the sample supernatant
and allocated in Eppendorf tubes at 801C until analysis.
ATP was measured by high-performance liquid chromatography
(HPLC) using a Thermo Quest (250 4.6 cm, 5 mm) column. Before
each analysis, the column was washed in water and then in 2%
methanol. An ATP standard curve was run prior to each set of
measurements. ATP was related to protein tissue content assayed by
the Bio-Rad method, using bovine serum albumin (Sigma Chemical
Co, St Louis, MO, USA) as a standard.
LDH process and analysis at 0, 24, 48 and 72 h
LDH release was measured using a commercially available kit (LDH
UV – Lab Test Diagnostica SA, Lagoa Santa, MG, Brazil) based on
the disappearance rate of nicotinamide adenine dinucleotide
(reduced form), detected at 340 nm, in the catalytic conversion of
pyruvate to lactate. The assay was performed in both the
supernatant and tissue homogenates. LDH release is expressed as
the ratio of the LDH in the medium to the total LDH (lysate).
Histological examination
Immediately after nephrectomy, slices of renal cortex were immersed
in Collins solution at 41C for 50 min. Then, slices were embedded in
22-oxacalcitriol, quickly frozen in liquid nitrogen and stored at
801C. Following cryosectioning, 5 mm sections were collected on
poly-L-lysine-coated slides, fixed in a 3.7% buffered paraformalde-
hyde (pH 7.4) solution for 15 min and then, washed twice in
phosphate-buffered saline, and three times for 10 min in 0.1%
Triton X-100 in a 1:1 mixture. Sections were incubated with
phalloidin-FITC (Sigma-Aldrich Corporate, St Louis, MO, USA),
13.2 mM in a 0.1% phosphate-buffered saline, and 0.5% Triton
X-100 solution (1:25 dilution) in a humidified chamber at 41C for
12 h. After two washings in phosphate-buffered saline for 10 min,
sections were stained with a 0.0001% Evans Blue solution (3 min),
washed again, mounted in Vectashields (Vector Laboratories,
Burlingame, CA, USA) and then examined with a fluorescence
microscope. Microphotographs of phalloidin-stained sections ( 40
objective lens) were obtained with a 400 ASA Fujichrome film (1 s
exposition) and sequentially subjected to visual inspection. Slides
were scanned and the apical fluorescence intensity of the proximal
tubule cells, indicative of the F-actin concentration, was measured
with a computer image analysis system using the Kellerman and
Bogusky25 method.
Statistics
As the data followed a normal distribution, analysis of variance
(one-way ANOVA) was used to compare ATP cell content and LDH
release among the groups and the Student–Newman–Keuls and
Bonferroni (for histological data) tests were used as post hoc;
Po0.05 was considered as significant.
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